Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.59
PRXL's Cash to Debt is ranked lower than
70% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. PRXL: 0.59 )
Ranked among companies with meaningful Cash to Debt only.
PRXL' s 10-Year Cash to Debt Range
Min: 0.35  Med: 14.71 Max: 336.54
Current: 0.59
0.35
336.54
Equity to Asset 0.36
PRXL's Equity to Asset is ranked lower than
83% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. PRXL: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
PRXL' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.46 Max: 0.64
Current: 0.36
0.3
0.64
F-Score: 6
Z-Score: 4.25
M-Score: -2.49
WACC vs ROIC
5.75%
21.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.58
PRXL's Operating margin (%) is ranked higher than
71% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. PRXL: 8.58 )
Ranked among companies with meaningful Operating margin (%) only.
PRXL' s 10-Year Operating margin (%) Range
Min: -1.77  Med: 6.15 Max: 8.8
Current: 8.58
-1.77
8.8
Net-margin (%) 6.34
PRXL's Net-margin (%) is ranked higher than
75% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. PRXL: 6.34 )
Ranked among companies with meaningful Net-margin (%) only.
PRXL' s 10-Year Net-margin (%) Range
Min: -5.24  Med: 3.35 Max: 6.34
Current: 6.34
-5.24
6.34
ROE (%) 24.54
PRXL's ROE (%) is ranked higher than
93% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. PRXL: 24.54 )
Ranked among companies with meaningful ROE (%) only.
PRXL' s 10-Year ROE (%) Range
Min: -15.55  Med: 9.70 Max: 23.79
Current: 24.54
-15.55
23.79
ROA (%) 8.13
PRXL's ROA (%) is ranked higher than
81% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. PRXL: 8.13 )
Ranked among companies with meaningful ROA (%) only.
PRXL' s 10-Year ROA (%) Range
Min: -7.19  Med: 3.70 Max: 7.99
Current: 8.13
-7.19
7.99
ROC (Joel Greenblatt) (%) 58.03
PRXL's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. PRXL: 58.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 1.08  Med: 27.15 Max: 58.04
Current: 58.03
1.08
58.04
Revenue Growth (3Y)(%) 15.90
PRXL's Revenue Growth (3Y)(%) is ranked higher than
87% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. PRXL: 15.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.3  Med: 15.30 Max: 23.9
Current: 15.9
5.3
23.9
EBITDA Growth (3Y)(%) 24.90
PRXL's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. PRXL: 24.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.9  Med: 14.30 Max: 56.3
Current: 24.9
-10.9
56.3
EPS Growth (3Y)(%) 36.20
PRXL's EPS Growth (3Y)(%) is ranked higher than
90% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. PRXL: 36.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.8  Med: 15.70 Max: 40.6
Current: 36.2
-26.8
40.6
» PRXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

PRXL Guru Trades in Q3 2014

Joel Greenblatt 774,370 sh (+169.71%)
Chuck Royce 455,000 sh (unchged)
Vanguard Health Care Fund 5,077,400 sh (unchged)
Ken Fisher 2,427,492 sh (-1.93%)
Jim Simons 719,600 sh (-2.35%)
Paul Tudor Jones 7,000 sh (-23.08%)
» More
Q4 2014

PRXL Guru Trades in Q4 2014

Steven Cohen 29,000 sh (New)
Joel Greenblatt 1,450,825 sh (+87.36%)
Paul Tudor Jones 7,900 sh (+12.86%)
Ken Fisher 2,455,751 sh (+1.16%)
Chuck Royce 455,000 sh (unchged)
Jim Simons 614,700 sh (-14.58%)
Vanguard Health Care Fund 4,292,200 sh (-15.46%)
» More
Q1 2015

PRXL Guru Trades in Q1 2015

Jim Simons 621,400 sh (+1.09%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 2,439,694 sh (-0.65%)
Vanguard Health Care Fund 3,790,200 sh (-11.70%)
Joel Greenblatt 1,265,994 sh (-12.74%)
Chuck Royce 385,100 sh (-15.36%)
» More
Q2 2015

PRXL Guru Trades in Q2 2015

Steven Cohen 409,200 sh (New)
Jim Simons 708,800 sh (+14.07%)
Vanguard Health Care Fund 3,790,200 sh (unchged)
Ken Fisher 2,431,850 sh (-0.32%)
Chuck Royce 337,400 sh (-12.39%)
Joel Greenblatt 918,656 sh (-27.44%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.41
PRXL's P/E(ttm) is ranked higher than
63% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.10 vs. PRXL: 25.41 )
Ranked among companies with meaningful P/E(ttm) only.
PRXL' s 10-Year P/E(ttm) Range
Min: 6.48  Med: 27.04 Max: 43.02
Current: 25.41
6.48
43.02
Forward P/E 20.79
PRXL's Forward P/E is ranked lower than
55% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.12 vs. PRXL: 20.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.60
PRXL's PE(NRI) is ranked higher than
63% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.30 vs. PRXL: 25.60 )
Ranked among companies with meaningful PE(NRI) only.
PRXL' s 10-Year PE(NRI) Range
Min: 6.5  Med: 27.08 Max: 43.02
Current: 25.6
6.5
43.02
P/B 5.68
PRXL's P/B is ranked lower than
76% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. PRXL: 5.68 )
Ranked among companies with meaningful P/B only.
PRXL' s 10-Year P/B Range
Min: 0.98  Med: 3.01 Max: 6.38
Current: 5.68
0.98
6.38
P/S 1.62
PRXL's P/S is ranked higher than
71% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. PRXL: 1.62 )
Ranked among companies with meaningful P/S only.
PRXL' s 10-Year P/S Range
Min: 0.33  Med: 1.05 Max: 1.77
Current: 1.62
0.33
1.77
PFCF 48.57
PRXL's PFCF is ranked lower than
58% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.28 vs. PRXL: 48.57 )
Ranked among companies with meaningful PFCF only.
PRXL' s 10-Year PFCF Range
Min: 9.43  Med: 20.64 Max: 99999999.99
Current: 48.57
9.43
99999999.99
POCF 23.86
PRXL's POCF is ranked higher than
54% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. PRXL: 23.86 )
Ranked among companies with meaningful POCF only.
PRXL' s 10-Year POCF Range
Min: 5.13  Med: 13.11 Max: 132.63
Current: 23.86
5.13
132.63
EV-to-EBIT 19.03
PRXL's EV-to-EBIT is ranked higher than
59% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.60 vs. PRXL: 19.03 )
Ranked among companies with meaningful EV-to-EBIT only.
PRXL' s 10-Year EV-to-EBIT Range
Min: -1612.8  Med: 17.70 Max: 238
Current: 19.03
-1612.8
238
PEG 1.29
PRXL's PEG is ranked higher than
76% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. PRXL: 1.29 )
Ranked among companies with meaningful PEG only.
PRXL' s 10-Year PEG Range
Min: 0.22  Med: 1.87 Max: 25.75
Current: 1.29
0.22
25.75
Shiller P/E 43.22
PRXL's Shiller P/E is ranked lower than
73% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.03 vs. PRXL: 43.22 )
Ranked among companies with meaningful Shiller P/E only.
PRXL' s 10-Year Shiller P/E Range
Min: 19  Med: 45.25 Max: 428.17
Current: 43.22
19
428.17
Current Ratio 1.50
PRXL's Current Ratio is ranked lower than
71% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. PRXL: 1.50 )
Ranked among companies with meaningful Current Ratio only.
PRXL' s 10-Year Current Ratio Range
Min: 1.34  Med: 1.62 Max: 2.36
Current: 1.5
1.34
2.36
Quick Ratio 1.50
PRXL's Quick Ratio is ranked lower than
62% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. PRXL: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
PRXL' s 10-Year Quick Ratio Range
Min: 1.34  Med: 1.62 Max: 2.36
Current: 1.5
1.34
2.36
Days Sales Outstanding 72.14
PRXL's Days Sales Outstanding is ranked lower than
81% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. PRXL: 72.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRXL' s 10-Year Days Sales Outstanding Range
Min: 61.59  Med: 131.34 Max: 194.86
Current: 72.14
61.59
194.86

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.50
PRXL's Price/Tangible Book is ranked lower than
90% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. PRXL: 22.50 )
Ranked among companies with meaningful Price/Tangible Book only.
PRXL' s 10-Year Price/Tangible Book Range
Min: 1.27  Med: 5.32 Max: 22.32
Current: 22.5
1.27
22.32
Price/Projected FCF 1.94
PRXL's Price/Projected FCF is ranked lower than
54% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. PRXL: 1.94 )
Ranked among companies with meaningful Price/Projected FCF only.
PRXL' s 10-Year Price/Projected FCF Range
Min: 1.71  Med: 2.60 Max: 8.33
Current: 1.94
1.71
8.33
Price/DCF (Earnings Based) 3.26
PRXL's Price/DCF (Earnings Based) is ranked lower than
60% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. PRXL: 3.26 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.54
PRXL's Price/Median PS Value is ranked lower than
82% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. PRXL: 1.54 )
Ranked among companies with meaningful Price/Median PS Value only.
PRXL' s 10-Year Price/Median PS Value Range
Min: 0.55  Med: 0.98 Max: 3.63
Current: 1.54
0.55
3.63
Price/Peter Lynch Fair Value 1.10
PRXL's Price/Peter Lynch Fair Value is ranked higher than
88% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. PRXL: 1.10 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PRXL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.85  Med: 2.03 Max: 5.84
Current: 1.1
0.85
5.84
Price/Graham Number 5.04
PRXL's Price/Graham Number is ranked lower than
86% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. PRXL: 5.04 )
Ranked among companies with meaningful Price/Graham Number only.
PRXL' s 10-Year Price/Graham Number Range
Min: 1.29  Med: 2.80 Max: 5.17
Current: 5.04
1.29
5.17
Earnings Yield (Greenblatt) (%) 5.25
PRXL's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. PRXL: 5.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRXL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.4  Med: 5.50 Max: 14.1
Current: 5.25
0.4
14.1
Forward Rate of Return (Yacktman) (%) 25.57
PRXL's Forward Rate of Return (Yacktman) (%) is ranked higher than
87% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. PRXL: 25.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PRXL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.3  Med: 16.20 Max: 36.3
Current: 25.57
3.3
36.3

Analyst Estimate

Jun16 Jun17 Jun18
Revenue(Mil) 2,187 2,335 2,466
EPS($) 3.25 3.93 4.42
EPS without NRI($) 3.25 3.93 4.42

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PAX.Germany,
Parexel International Corp was incorporated in 1983. The Company provides clinical research, medical communications, consulting, commercialization and informatics and advanced technology services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company has three reporting segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). CRS constitutes its core business and include all phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice (GMP) compliance consulting. In addition, PCMS provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PCMS consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. Additionally, PCMS provides reimbursement and market access (RMA) services. Perceptive provides information technology solutions designed to improve clients' product development processes. Perceptive's portfolio of products and services includes ClinPhone RTSM, medical imaging services, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite. It competes with other biopharmaceutical services companies and other clinical research organizations (CROs) that provide one or more of the services being offered by it. Some of the biopharmaceutical services companies, such as Quintiles Transnational Corporation, Covance Inc., Pharmaceutical Product Development Inc., inVentiv Health, INC Research, and Icon plc, offer services that compete directly with its services at many levels.
» More Articles for PRXL

Headlines

Articles On GuruFocus.com
Parexcel: Great Growth but a Tough Business Aug 17 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 12,920 Shares Mar 11 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 1,500 Shares Mar 11 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Feb 09 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Nov 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K/A) Sep 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K) Aug 27 2010 
PAREXEL International Corp. Reports Operating Results (10-Q) May 07 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 13,149 Shares Mar 12 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 15,600 Shares Mar 04 2010 

More From Other Websites
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 26 2015
PAREXEL Names Maykin Ho to Board of Directors Aug 26 2015
PAREXEL INTERNATIONAL CORP Files SEC form 10-K, Annual Report Aug 25 2015
New Highs Include Breakouts: First American, MI Homes Aug 17 2015
Credit Suisse Sees Big Biopharma Upside in Top Contract Research Outfits Aug 16 2015
PAREXEL Receives CEO Cancer Gold Standard Accreditation Aug 13 2015
Edited Transcript of PRXL earnings conference call or presentation 6-Aug-15 2:00pm GMT Aug 06 2015
PAREXEL International Corp Earnings Call scheduled for 10:00 am ET today Aug 06 2015
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2015
Parexel tops 4Q profit forecasts Aug 05 2015
Parexel tops 4Q profit forecasts Aug 05 2015
PAREXEL International Reports Fourth Quarter And Fiscal Year 2015 Results; Confirms Previous Revenue... Aug 05 2015
Q4 2015 PAREXEL International Corp Earnings Release - After Market Close Aug 05 2015
Billionaire Ken Fisher Loves These Small-Cap Stocks Jul 26 2015
Signet Jewelers Set to Join the S&P 500; PAREXEL International, Catalent to Join the S&P MidCap 400;... Jul 24 2015
PAREXEL Launches Next Generation Analytics Capabilities Within Perceptive MyTrials® Platform Jul 21 2015
PAREXEL (PRXL) Expands In Model-Based Drug Development - Analyst Blog Jul 13 2015
PAREXEL Expands Model-Based Drug Development Offering Jul 09 2015
PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And... Jul 07 2015
Edited Transcript of PRXL corporate analyst meeting Jun 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK